Biotech 2050 Podcast

Dr. Matthew Bio is President & CEO at Snapdragon Chemistry. Matthew began his career in chemistry more than 20 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck R...

Alexander Titus is the Founder of Bioeconomy. XYZ and the Chief Strategy Officer (CSO) at the Advanced Regenerative Manufacturing Institute (ARMI), where his career focuses on the intersection of technology and public benefit, with experience spanning the private and public sectors, as well as non-profits and academia. In previous roles, Alexander was the inaugural Assistant Director (AD) for Biot...

James Burns, PhD, Chief Executive Officer, Locanabio James (Jim) Burns, Ph. D., joined Locanabio in December 2019 as CEO and Board member. Prior to joining Locanabio, Dr. Burns served as the CEO of Casebia Therapeutics and led the team in discovering and developing new CRISPR/Cas9-based breakthrough therapeutics to treat blood disorders, blindness and auto-immune disease. Prior to Casebia, Dr. Bur...

Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin a...

Victor Hanson-Smith is the Head of Computational Biology at Verge Genomics and is one of the world's leaders in mathematical modeling of eukaryotic genome evolution and function. He has co-authored 13 publications in peer-reviewed journals such as Nature and Science, and his work has been featured in the NYTimes and The Washington Post. He received his Ph. D. in Computer Science from the Universit...

Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in...

Bob has been President of Imagion Biosystems since February 2015 and has led the company through the recent restructuring and recapitalization efforts. Previous employment experience includes Pres/GM for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries, e.g. Vice President Marketing...

Nick Damiano is a serial entrepreneur with broad experience in medical devices and digital health. He has 15 years of experience as a healthcare entrepreneur, engineer, and leader. He is currently Co-Founder & CEO of Zenflow, which is developing a novel office-based therapy to relieve symptoms of benign prostatic hyperplasia (BPH), which affects over 500 million men globally. The company has raise...

Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph. D. in Biochemistry and Molecular Biology from Johns Hopkins Unive...

Dr. Paul R. Billings is a board-certified internist and clinical geneticist, who also holds a PhD in Immunology, from Harvard University. He worked there with Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. In 2018, Dr. Billings became the Chief Medical Officer and Senior Vice President for Medical Affairs at Natera. Dr Billings recently has been a Partner in the diagn...

Andy Protter, PhD. joined Auransa in January 2017 as Chief Scientific Officer with 35 years of pharmaceutical industry research and development experience. At Auransa, Dr. Protter has led preclinical R&D which uses AI technology to discover novel drug candidates. Auransa’s lead project for hepatocellular carcinoma has completed all IND-supporting preclinical safety studies. Prior to joining Aurans...

JoyL is the General Manager of Pfizer CentreOne, a global contract development and manufacturing organization (CDMO) and a leading supplier of specialty APIs embedded within Pfizer. In 2019, under her leadership, Pfizer CentreOne contributed $810M in revenue with a growth rate of 9% while advancing Pfizer’s purpose of delivering breakthroughs that change patients’ lives. In 2020 Pfizer CentreOne r...

Abbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Abbas joined Nimbus in 2014 as Director of Business Development and has driven several of the company’s key transactions that have brought over $775M into Nimbus through...

Dr. Randy Schatzman, Ph. D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company thr...

Dr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University. He led a basic and translational research laboratory-his research focused on the study of dysregulated signaling in fibrosi...

Diego is currently the Head of Research & Development of Global Rare Diseases at the Chiesi Group. Before this role, he was leading Chiesi’s development projects in rare diseases and advanced therapies and has more than 10 years experience in drug development, spanning from pre-clinical to commercial phase. Diego is an MD with a specialization in Internal Medicine. He obtained a PhD at the Univers...

Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer and as one of our directors since our inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, where he was most recently Vice President, Lilly Research Labo...

Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she is Executive Chairman (formerly CEO) of ProterixBio, and serves on the boards of CareDx (NASDAQ:CDNA) and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Formerly, she was a partner...

Recorded in January 2020, we spoke with Sachin Chandran, who is currently Executive Director and Head of Pharmaceutical Sciences at Catabasis Pharmaceuticals, Inc. in Boston. Sachin’s responsibilities include oversight of CMC, Tech-Ops and supply chain along with matrixed interactions with regulatory, quality, biology, clinical and commercial. Working in a lean organization and a virtual environme...

Mike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA. He holds a BA from Stanford University and an MBA from C...

David Mace is the Co-founder & CEO of SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge. Previously David was an Entrepreneur in Residence at 8VC, where he focused on the intersection of biology & computer s...

David Bates is a scientist, inventor, investor, and entrepreneur. He has co-founded several companies including Linus Health and Bode. He is a founding partner of Tamarisc Ventures and serves on the board of several high-growth technology companies. He is on the board of directors of TMCity Foundation and is Strategic Advisor to the Digital Medicine Society. He previously worked at Morningside Ven...

Stephan is a co-Founder and Chief Scientific Officer at Anokion, bringing more than 15 years of research expertise in the fields of immunology, protein engineering, and platform technologies to the company. He earned his B.Sc. in Chemical Engineering from the University of Texas at Austin and a Ph. D. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne. During his t...

Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a va...

Dr. Paul K. Wotton is the Chief Executive Officer at Obsidian Therapeutics. Obsidian is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timi...